Image_1_Antioxidants and the risk of sleep disorders: results from NHANES and two-sample Mendelian randomization study.pdf حسب Junjie Jiang (7255706)

"…Additionally, a two-sample Mendelian randomization analysis was conducted to explore the potential causal link between CDAI and the risk of sleep disorders.</p>Results<p>Analysis of data from the 2007–2018 NHANES survey revealed a significant negative association between CDAI and sleep disorders (OR = 0.854, 95% CI 0.821–0.888, P < 0.001). …"

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff حسب Øystein Fluge (200378)

"…For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8–9 months (p = 0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). …"

Data Sheet 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf حسب figshare admin frontiersin (4545187)

"…For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8–9 months (p = 0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). …"

Data Sheet 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf حسب Øystein Fluge (200378)

"…For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8–9 months (p = 0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). …"

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff حسب Øystein Fluge (200378)

"…For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8–9 months (p = 0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). …"

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff حسب Øystein Fluge (200378)

"…For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8–9 months (p = 0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). …"

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx حسب Øystein Fluge (200378)

"…For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8–9 months (p = 0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). …"

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff حسب Øystein Fluge (200378)

"…For all 10 patients, mean SF-36 Physical Function (SF-36 PF) increased from 25.9 to 55.0 at 8–9 months (p = 0.002). DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). …"

Voltage-Assisted Sonication for the Generation of Liquid Metal Particles حسب Nur-Adania Nor-Azman (18369256)

Voltage-Assisted Sonication for the Generation of Liquid Metal Particles حسب Nur-Adania Nor-Azman (18369256)

Voltage-Assisted Sonication for the Generation of Liquid Metal Particles حسب Nur-Adania Nor-Azman (18369256)

Supplementary file 1_From lockdown to recovery: changing patterns of viral infection severity in a pediatric cohort with asthma.docx حسب Cassidy Jones (22301638)

"…RV/EV was the most common virus during all periods. Viral incidence decreased during NPIs but rebounded post-NPI with unusual seasonality. mWHO OSI scores declined over time (pre-NPI: 2.98; NPI: 2.49; post-NPI: 2.28), with significant reductions in hospitalizations, PICU admissions, and oxygen use (p < 0.0001). …"

<b>Precursor and Mature miRNA Sequences from the Hepatopancreas of Macrobrachium rosenbergii under Low-Temperature Stress</b> حسب jinlin gong (21467675)

"…<p dir="ltr">All <i>Macrobrachium rosenbergii</i> individuals used in this study were sourced from Jiangsu Shufeng Aquatic Seed Industry Co., Ltd. …"

Table 3_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.docx حسب Jia-Yi Wang (490704)

"…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…"

Image 1_Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study.jpeg حسب Shuangmei Zhang (1807303)

"…Correlations between biomarkers and clinical improvements were analyzed.</p>Results<p>By week 24, secukinumab treatment led to significant reductions in disease severity scores (QMG: 60.7%; MG-QOL15: 58.3%; MG-ADL: 64.1%) and AChR antibody levels (69.23%). …"

Table 2_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx حسب Jia-Yi Wang (490704)

"…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…"

Data Sheet 1_Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study.pdf حسب Shuangmei Zhang (1807303)

"…Correlations between biomarkers and clinical improvements were analyzed.</p>Results<p>By week 24, secukinumab treatment led to significant reductions in disease severity scores (QMG: 60.7%; MG-QOL15: 58.3%; MG-ADL: 64.1%) and AChR antibody levels (69.23%). …"

Efficacy and Safety of Topical Loteprednol Etaponate 0.5% and Topical Dexamethasone 0.1% in Post Cataract Surgery in Iraqi Patients. .csv حسب Leqaa Taha (20141172)

"…The intraocular pressure was measured preoperatively and was rechecked one week and four weeks after the surgery.</p><p dir="ltr"><b>Results:</b> Sixty-six eyes of 66 patients were enrolled (33 patients in group A and 33 in group B) with no clinically significant differences related to age or gender between the two groups, the intraocular pressure was 16.45 ± 3.00, and 16.42± 2.76 mmHg in group A and B respectively preoperatively which was clinically insignificant with p-value 0.522 and decreased slightly after the surgery 15.82± 3.005 and 15.61± 2.817mmHg in group A and B respectively after one week postoperatively but also clinically insignificant and was 15.58± 2.211 and 16.55± 4.452 mmHg in group A and B after four weeks postoperatively and all these changes in IOP was clinically insignificant.…"

Table 1_From lockdown to recovery: changing patterns of viral infection severity in a pediatric cohort with asthma.docx حسب Cassidy Jones (22301638)

"…RV/EV was the most common virus during all periods. Viral incidence decreased during NPIs but rebounded post-NPI with unusual seasonality. mWHO OSI scores declined over time (pre-NPI: 2.98; NPI: 2.49; post-NPI: 2.28), with significant reductions in hospitalizations, PICU admissions, and oxygen use (p < 0.0001). …"

Table 1_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx حسب Jia-Yi Wang (490704)

"…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…"